Effects of Pegylated Glucagon-Like Peptide-1 Analogue in C57Bl/6 Mice under Optimal Conditions and During Streptozotocin-Induced Diabetes
- 26 September 2017
- journal article
- Published by Springer Science and Business Media LLC in Bulletin of Experimental Biology and Medicine
- Vol. 163 (5), 635-638
- https://doi.org/10.1007/s10517-017-3867-y
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic TissuesPancreas, 2016
- Differentiation of Pancreatic Stem and Progenitor β-Cells into Insulin Secreting Cells in Mice with Diabetes MellitusBulletin of Experimental Biology and Medicine, 2014
- Type 1 Diabetes: Etiology, Immunology, and Therapeutic StrategiesPhysiological Reviews, 2011
- PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db miceDiabetologia, 2006
- Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pigDiabetologia, 2005
- The Glucagon-Like PeptidesEndocrine Reviews, 1999
- Glucagon-Like Peptide-1-(7–36)Amide Is Transformed to Glucagon-Like Peptide-1-(9–36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1Endocrinology, 1999
- Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.Endocrinology, 1995